Circulating Tumor Cells: Evolving Role in Pathologic Analysis and Clinical Decision MakingAragon-Ching, Jeanny B. MD*; Nolan, Norris MD†; Schwartz, Arnold M. MD, PhD†‡Pathology Case Reviews: September/October 2014 - Volume 19 - Issue 5 - p 229–233 doi: 10.1097/PCR.0000000000000051 Case Reviews Buy Abstract Author InformationAuthors Article MetricsMetrics The identification of circulating tumor cells (CTCs) in patients with solid cancers represents a putative biomarker that may be associated with disease progression and metastatic behavior. The technique of enumerating CTCs has been reported to enable improved disease prognostication and monitoring of treatment. As a result, this approach has gained increasing interest in the field of cancer management and prognosis. Several studies have shown utility in a variety of clinical conditions, ranging from early localized disease to disseminated metastatic cancer. We present the potential application of CTC determination in 2 patients with prostate cancer. Understanding its potential prognostic information as well as its methodological limitations is of paramount importance in order to better interpret the results in the context of a particular patient with cancer. From the *Division of Hematology and Oncology, Department of Internal Medicine, and Departments of †Pathology and ‡Surgery, The George Washington University, Washington, DC. Reprints: Arnold M. Schwartz, MD, PhD, Department of Pathology, The George Washington University Medical Center, 900 23rd St NW, Washington, DC 20037. E-mail: email@example.com. This work was funded in part by the Dr Cyrus and Myrtle Katzen Cancer Research Center at The George Washington University. © 2014 by Lippincott Williams & Wilkins.